BioCardia Amends S-1, Reveals Ongoing Capital Raises & Governance Shifts

TL;DR

**BioCardia's S-1/A is a red flag, signaling continuous dilution risk as the company scrambles for cash through multiple offerings to stay afloat.**

AI Summary

BioCardia, Inc. filed an S-1/A on September 17, 2025, primarily as an exhibits-only amendment to its existing S-1 registration statement (File No. 333-290283). This filing does not introduce new financial results but updates the exhibit list, indicating ongoing capital raising and corporate governance activities. Key updates include an engagement letter with H.C. Wainwright & Co., LLC dated February 26, 2024, and several Securities Purchase and Registration Rights Agreements from December 14, 2022, February 9, 2024, April 22, 2025, and June 30, 2025, suggesting continuous efforts to secure funding. The company also updated its Amended and Restated Certificate of Incorporation on May 29, 2024, and filed amendments to Change of Control and Severance Agreements for Peter Altman and David McClung on May 30, 2024. The filing confirms BioCardia is a 'smaller reporting company' and an 'emerging growth company,' indicating its stage of development and regulatory compliance status. No specific revenue or net income figures are provided in this exhibits-only amendment.

Why It Matters

This S-1/A filing signals BioCardia's persistent need for capital, evidenced by multiple Securities Purchase and Registration Rights Agreements spanning 2022 to 2025. For investors, this indicates potential dilution from future offerings and a reliance on external funding to advance its pipeline. Employees and customers might see this as a sign of continued operational efforts, but also highlights the financial pressures on a clinical-stage biotech. The competitive landscape in regenerative medicine demands significant investment, and BioCardia's frequent capital raises suggest it's actively trying to keep pace, though without new financial data, the efficacy of these efforts remains unclear.

Risk Assessment

Risk Level: high — The filing is an exhibits-only amendment, meaning no new financial data is presented to assess current performance. However, the sheer number of Securities Purchase and Registration Rights Agreements (dated December 14, 2022, February 9, 2024, April 22, 2025, and June 30, 2025) strongly suggests ongoing and frequent capital raises, which typically lead to significant shareholder dilution. This continuous need for external funding, without updated financial context, indicates a high operational risk and potential for further stock price volatility.

Analyst Insight

Investors should exercise extreme caution and thoroughly review BioCardia's most recent full financial statements (e.g., 10-K filed March 26, 2025) to understand its cash burn and runway. Given the pattern of frequent capital raises, consider the high risk of further dilution before making any investment decisions. This filing primarily serves as a notice of ongoing financing activities, not a positive catalyst.

Key Numbers

• 2025-09-17 — Filing Date (Date of S-1/A filing)
• 333-290283 — Registration No. (SEC registration statement number)
• 2024-02-26 — Engagement Letter Date (Date of engagement letter with H.C. Wainwright & Co., LLC)
• 2022-12-14 — Securities Purchase Agreement Date (Date of first listed Securities Purchase and Registration Rights Agreement)
• 2025-06-30 — Securities Purchase Agreement Date (Date of most recent listed Securities Purchase and Registration Rights Agreement)
• 2024-05-29 — Certificate of Incorporation Amendment Date (Date of Amended and Restated Certificate of Incorporation amendment)
• 2024-05-30 — Severance Agreement Amendment Date (Date of executive severance agreement amendments)

Key Players & Entities

• BioCardia, Inc. (company) — Registrant
• H.C. Wainwright & Co., LLC (company) — Underwriter/Placement Agent
• Peter Altman (person) — President and Chief Executive Officer
• David McClung (person) — Chief Financial Officer
• Wilson Sonsini Goodrich & Rosati, P.C. (company) — Legal Counsel
• Biomet Biologics, LLC (company) — License and Distribution Agreement partner
• BSLF, LLC (company) — Litigation Funding provider
• The Irvine Company LLC (company) — Lessor
• Cantor Fitzgerald & Co. (company) — Controlled Equity Offering Sales Agent
• PKF San Diego, LLP (company) — Independent Registered Public Accounting Firm

FAQ

Risk Factors

• Ongoing Capital Raising Efforts [high — financial]: The company has entered into multiple Securities Purchase and Registration Rights Agreements between December 14, 2022, and June 30, 2025. This indicates a continuous need for external funding, suggesting potential financial instability or significant investment requirements for its operations and development pipeline.
• Emerging Growth Company Status [medium — regulatory]: BioCardia is identified as an 'emerging growth company.' This status provides certain regulatory and disclosure accommodations but also implies a less mature operational and financial structure compared to larger, established public companies.
• Amended Severance Agreements [medium — legal]: Amendments to Change of Control and Severance Agreements for Peter Altman and David McClung were filed on May 30, 2024. Such agreements can represent significant future financial obligations for the company in specific scenarios, impacting its financial flexibility.

Industry Context

BioCardia operates in the biotechnology sector, focusing on developing therapies for cardiovascular diseases. This industry is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. The competitive landscape includes both large pharmaceutical companies and numerous smaller biotech firms, all vying for market share and investor capital.

Regulatory Implications

As an emerging growth company and smaller reporting company, BioCardia benefits from reduced disclosure requirements. However, it must still comply with SEC regulations and maintain accurate reporting. Any future product approvals will be subject to rigorous FDA review, posing significant regulatory risks.

What Investors Should Do

1. Monitor future SEC filings for updated financial results and disclosures.
2. Evaluate the company's ongoing capital needs and funding strategies.
3. Assess the progress of BioCardia's therapeutic pipeline and regulatory milestones.

Key Dates

• 2025-09-17: S-1/A Filing Date — Indicates ongoing corporate activities and potential capital raising efforts, as this is an exhibits-only amendment to an existing registration statement.
• 2024-02-26: Engagement Letter with H.C. Wainwright & Co., LLC — Suggests the company is actively engaging financial advisors, likely for capital raising or strategic transactions.
• 2022-12-14: First Securities Purchase and Registration Rights Agreement — Marks the beginning of a series of agreements aimed at securing funding through equity or debt issuances, highlighting a consistent need for capital.
• 2025-06-30: Most Recent Securities Purchase and Registration Rights Agreement — Demonstrates continued reliance on these agreements for financing, underscoring the ongoing capital requirements of the company.
• 2024-05-29: Amended and Restated Certificate of Incorporation — Indicates corporate structure changes or updates, which can be related to governance, share structure, or preparation for future events.
• 2024-05-30: Severance Agreement Amendments for Executives — Highlights potential changes in executive compensation or change-of-control provisions, which can have financial implications for the company.

Glossary

S-1/A

An amendment to an S-1 registration statement filed with the SEC. It is used to update or correct information previously filed. (This filing is an S-1/A, indicating BioCardia is updating its registration statement, likely for ongoing capital raising or corporate actions.)

Emerging Growth Company

A designation for companies with less than $1.235 billion in annual gross revenue that are allowed certain accommodations under the JOBS Act, including reduced disclosure requirements. (BioCardia's status as an EGC affects its reporting obligations and compliance burden.)

Smaller Reporting Company

A company that meets certain criteria regarding public float and annual revenue, allowing for scaled-down disclosure requirements. (This status, along with EGC, indicates BioCardia is in an earlier stage of development and has fewer reporting obligations.)

Securities Purchase Agreement

A contract between a seller and a buyer for the sale of securities, outlining terms, conditions, and price. (Multiple such agreements filed suggest BioCardia is actively raising capital through the sale of its securities.)

Registration Rights Agreement

An agreement granting holders of securities the right to have their securities registered with the SEC for public resale. (Often paired with purchase agreements, these rights facilitate the liquidity of securities issued in private placements.)

Engagement Letter

A formal agreement outlining the terms of service between a client and a professional firm, such as an investment bank. (The engagement letter with H.C. Wainwright & Co., LLC suggests the company is working with financial advisors, likely for capital raising.)

Year-Over-Year Comparison

This filing is an exhibits-only amendment to an existing S-1 registration statement and does not contain updated financial results compared to previous filings. Therefore, a direct comparison of key metrics like revenue growth, margin changes, or new risks is not possible based on this specific document. The filing primarily serves to update the exhibit list, reflecting ongoing corporate activities such as capital raising and executive agreement amendments.

Filing Documents

• bcda20250916_s1a.htm (S-1/A) — 74KB
• ex_862079.htm (EX-1.1) — 120KB
• hcw.jpg (GRAPHIC) — 25KB
• 0001437749-25-029214.txt ( ) — 230KB

Exhibits and Financial Statement Schedules

Item 16. Exhibits and Financial Statement Schedules (a) Exhibits. Exhibit Index Exhibit Number Description 1.1*+ Engagement letter, dated February 26, 2024, as subsequently amended, by and between BioCardia, Inc. and H.C. Wainwright & Co., LLC 2.1(1) Agreement and Plan of Merger dated August 22, 2016 2.2(2) First Amendment to Agreement and Plan of Merger dated October 21, 2016 3.1(3) Amended and Restated Certificate of Incorporation, as amended May 29, 2024 3.2(4) Amended and Restated Bylaws 4.1(5) Specimen common stock certificate 4.2(6) BioCardia 2002 Stock Plan, as amended 4.3(7) Form of Stock Option Agreement under BioCardia 2002 Stock Plan 4.4(8) BioCardia 2016 Equity Incentive Plan, as amended 4.5(9) Form of Stock Option Agreement under BioCardia 2016 Equity Incentive Plan 4.6(10) Form of Restricted Stock Unit Agreement under BioCardia 2016 Equity Inventive Plan 4.7(11) Form of Pre-Funded Warrant in connection with this offering 4.8(12) Form of Common Warrant in connection with this offering 4.9(13) Form of Director Restricted Stock Unit Agreement under the BioCardia 2016 Equity Incentive Plan 4.10(14) Form of Securities Purchase and Registration Rights Agreement, dated December 14, 2022, between the Company and certain qualified institutional buyers and institutional accredited investors II-1 Exhibit Number Description 4.11(15) Form of Securities Purchase and Registration Rights Agreement, dated February 9, 2024, by and among the Company and certain qualified institutional buyers and institutional accredited investors (including the Form of Warrant attached as Exhibit A thereto) 4.12(16) Form of Warrant to Purchase Shares of Common Stock 4.13(17) Form of Securities Purchase and Registration Rights Agreement, dated April 22, 2025, by and among the Company and the Investors 4.14(18) Form of Securities Purchase and Registration Rights Agreement, dated June 30, 2025, by and among the Compan

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Amendment No. 1 to FormS-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Sunnyvale, State of California, on September 17, 2025. BIOCARDIA, INC. By: /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated: Signature Title Date /s/ Peter Altman, Ph.D. President and Chief Executive Officer and Director September 17, 2025 Peter Altman, Ph.D. (Principal Executive Officer) /s/ David McClung Chief Financial Officer September 17, 2025 David McClung (Principal Financial and Accounting Officer) * Director September 17, 2025 Andrew Blank * Director September 17, 2025 Jim Allen * Director September 17, 2025 Bill Facteau * Director September 17, 2025 Richard Krasno, Ph.D. * Director September 17, 2025 Jay M. Moyes * Director September 17, 2025 Simon Stertzer, M.D. *Pursuant to power of attorney By: /s/ Peter Altman Peter Altman, Ph.D. Attorney-in-fact II-4

View Full Filing

View this S-1/A filing on SEC EDGAR